A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin

Novo Nordisk A/S81 enrolled

Overview

This study is conducted in Japan. The aim of the study is to evaluate the efficacy of somatropin (Norditropin®) on adult height (cm) in patients with achondroplasia / hypochondroplasia enrolled in the GH-1941 study (NCT01516229).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Genetic Disorder Achondroplasia

Interventions

somatropinDRUG

Dosage and administration to be prescribed by the physician as a result of a normal clinical practice.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who were enrolled in the GH-1941 study (1997 to 2006) and expected to theoretically reach the adult height within the study period

Locations (1)

Novo Nordisk Investigational Site

Tokyo, Japan

Outcomes

Primary Outcomes

To collect change data of adult height (cm) of patients treated with Norditropin® and evaluate the long-term efficacy

Time frame: At year 1, 2, 3, 4, and 5 after the patient has reached adult height or is 18 of age

Secondary Outcomes

To monitor the patients to see if they undergo lower limb lengthening

Time frame: At year 1, 2, 3, 4, and 5 after the patient has reached adult height or is 18 of age

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.